A study investigating the use of Prevo-Check® for the early detection of HPV16-induced anal cancer has been shortlisted for a UK Diagnostics Award in the category “Pilot of the Year”. Conducted by the German Competence Network for HIV/AIDS, the retrospective study showed that Prevo-Check® would have helped achieving an anal cancer diagnosis up to 9.5…
Read More
Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying…
Read More
Abviris GmbH Obtains Almost 3 Million Euros in Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that…
Read More A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®. Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal…
Read More Rochester, MN (USA) / Ahrensburg, Germany: Mayo Clinic and Abviris Deutschland GmbH have successfully signed a cooperation agreement for preclinical research into the diagnostics of HPV induced cancer. Mayo Clinic is one of the leading healthcare and medical research centers of the world. HPV and cancer HPV is responsible for 5% of all cancers, men…
Read More
